Immix Biopharma Inc. (IMMX)
1.61
-0.02 (-1.23%)
At close: Mar 13, 2025, 11:28 AM
-1.23% (1D)
| Bid | 1.61 |
| Market Cap | 44.29M |
| Revenue (ttm) | 4.47K |
| Net Income (ttm) | -20.46M |
| EPS (ttm) | -0.84 |
| PE Ratio (ttm) | -1.92 |
| Forward PE | -2.86 |
| Analyst | Buy |
| Ask | 2.07 |
| Volume | 2,657 |
| Avg. Volume (20D) | 101,436 |
| Open | 1.61 |
| Previous Close | 1.63 |
| Day's Range | 1.60 - 1.61 |
| 52-Week Range | 1.26 - 3.35 |
| Beta | 0.25 |
About IMMX
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the tr...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 16, 2021
Employees 14
Stock Exchange NASDAQ
Ticker Symbol IMMX
Website https://www.immixbio.com
Analyst Forecast
According to 1 analyst ratings, the average rating for IMMX stock is "Buy." The 12-month stock price forecast is $7, which is an increase of 334.78% from the latest price.
Stock Forecasts
2 years ago · pennystocks.com
Penny Stocks To Buy? 4 To Watch Before Next WeekHot penny stocks to watch this week. The post Penny Stocks To Buy?